WO2006062946A3 - Incorporation of bone marrow derived stem cells in tumors - Google Patents

Incorporation of bone marrow derived stem cells in tumors Download PDF

Info

Publication number
WO2006062946A3
WO2006062946A3 PCT/US2005/044066 US2005044066W WO2006062946A3 WO 2006062946 A3 WO2006062946 A3 WO 2006062946A3 US 2005044066 W US2005044066 W US 2005044066W WO 2006062946 A3 WO2006062946 A3 WO 2006062946A3
Authority
WO
WIPO (PCT)
Prior art keywords
bone marrow
tumors
incorporation
stem cells
derived stem
Prior art date
Application number
PCT/US2005/044066
Other languages
French (fr)
Other versions
WO2006062946A2 (en
Inventor
Christopher R Cogle
Edward W Scott
Original Assignee
Univ Florida
Christopher R Cogle
Edward W Scott
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Florida, Christopher R Cogle, Edward W Scott filed Critical Univ Florida
Publication of WO2006062946A2 publication Critical patent/WO2006062946A2/en
Publication of WO2006062946A3 publication Critical patent/WO2006062946A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Circulating bone marrow cells have been found to contribute to growth of colonic adenomas. Recipients of gender-mismatched transplants showed evidence of Y-chromosome positive epithelial cells, accounting for 1 to 4% of the cells in histologic section. Furthermore, there was no evidence of fusion events by confocal microscopic genotypic analysis. Compositions and methods of treatment of cancer patients, are described.
PCT/US2005/044066 2004-12-06 2005-12-06 Incorporation of bone marrow derived stem cells in tumors WO2006062946A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63351504P 2004-12-06 2004-12-06
US60/633,515 2004-12-06

Publications (2)

Publication Number Publication Date
WO2006062946A2 WO2006062946A2 (en) 2006-06-15
WO2006062946A3 true WO2006062946A3 (en) 2006-09-21

Family

ID=36578477

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/044066 WO2006062946A2 (en) 2004-12-06 2005-12-06 Incorporation of bone marrow derived stem cells in tumors

Country Status (1)

Country Link
WO (1) WO2006062946A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9109002B2 (en) 2011-12-22 2015-08-18 Glycomimetics, Inc. E-selectin antagonist compounds, compositions, and methods of use
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008336249B2 (en) 2007-12-10 2015-01-29 The University Of Queensland Treatment and prophylaxis
EP2496604B1 (en) 2009-11-06 2017-08-23 IDEXX Laboratories, Inc. Canine anti-cd20 antibodies
ES2668045T3 (en) 2012-12-07 2018-05-16 Glycomimetics, Inc. Compounds, compositions and methods that use E-selectin antagonists for the mobilization of hematopoietic cells
EP3227310B1 (en) 2014-12-03 2019-07-31 GlycoMimetics, Inc. Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors
US11291678B2 (en) 2016-03-02 2022-04-05 Glycomimetics, Inc Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin
WO2018031445A1 (en) 2016-08-08 2018-02-15 Glycomimetics, Inc. Combination of t-cell checkpoint inhibitors with inhibitors of e-selectin or cxcr4, or with heterobifunctional inhibitors of both e-selectin and cxcr4
JP7069136B2 (en) 2016-10-07 2022-05-17 グリコミメティクス， インコーポレイテッド Extremely potent multimeric E-selectin antagonist
EP3596096A1 (en) 2017-03-15 2020-01-22 GlycoMimetics, Inc. Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
US11712446B2 (en) 2017-11-30 2023-08-01 Glycomimetics, Inc. Methods of mobilizing marrow infiltrating lymphocytes and uses thereof
WO2019133878A1 (en) 2017-12-29 2019-07-04 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectin and galectin-3
AU2019230013A1 (en) 2018-03-05 2020-09-10 Glycomimetics, Inc. Methods for treating acute myeloid leukemia and related conditions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003091398A2 (en) * 2002-04-23 2003-11-06 Roger Williams Hospital Compositions and methods for stem cell delivery

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003091398A2 (en) * 2002-04-23 2003-11-06 Roger Williams Hospital Compositions and methods for stem cell delivery

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LUM L.G. ET AL: "Targeting of Lin-Sca+ hematopoietic stem cells with bispecific antibodies to injured myocardium", BLOOD CELLS, MOLECULES AND DISEASES, vol. 32, 2004, pages 82 - 87, XP003004212 *
WANG G. ET AL: "A T cell-independent antitumor response in mice with bone marrow cells retrovirally transduced with an antibody/Fc-gamma chain chimeric receptor gene recognizing a human ovarian cancer antigen", NAT. MED., vol. 4, no. 2, 1998, pages 168 - 172, XP008072830 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9109002B2 (en) 2011-12-22 2015-08-18 Glycomimetics, Inc. E-selectin antagonist compounds, compositions, and methods of use
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3

Also Published As

Publication number Publication date
WO2006062946A2 (en) 2006-06-15

Similar Documents

Publication Publication Date Title
WO2006062946A3 (en) Incorporation of bone marrow derived stem cells in tumors
GB2392674A (en) Mesenchymal cells and osteoblasts from human embryonic stem cell
Brini et al. Cell-mediated drug delivery by gingival interdental papilla mesenchymal stromal cells (GinPa-MSCs) loaded with paclitaxel
WO2005070447A3 (en) M-csf muteins and uses thereof
BRPI0618488A2 (en) Hepatocyte Growth Factor Intron Fusion Proteins
WO2007047766A3 (en) Methods for rejuvenating cells in vitro and in vivo
WO2005070090A3 (en) Regulatory t cells suppress autoimmunity
WO2003059276A3 (en) Novel mammalian multipotent stem cells and compositions, methods of preparation and methods of administration thereof
SG164368A1 (en) Treatment of cancer
UA96301C2 (en) Substituted phenylsulfur trifluoride and other like fluorinating agents
WO2001057082A3 (en) Extraction of growth factors from tissue
TW200619287A (en) Composition and method
Chang et al. Toxic effects of gentamicin on marrow-derived human mesenchymal stem cells
TW200635949A (en) Tripeptide and tetrapeptide sulfones
WO2006001938A3 (en) Methods and compositions for producing germ cells from bone marrow derived germline stem cells
WO2007149287A3 (en) Transfer factor compositions and methods
WO2009094456A3 (en) Use of high-dose, post-transplantation oxazaphosphorine drugs for reduction of transplant rejection
WO2007011595A3 (en) Neural regeneration peptides and antioxidants protect neurons from degeneration
MX2008014395A (en) Composition for the treatment of resistant cancers comprising oridonin.
TW200505501A (en) CCI-779 lyophilized formulations
WO2007076087A3 (en) 3-aryl-substituted quinazolones, and uses thereof
WO2012067437A3 (en) Composition for increasing liver volume for the purpose of liver resection
WO2007109648A3 (en) Compositions and methods for modulating store-operated calcium entry
WO2006116185A3 (en) Methods for the treatment of multiple myeloma
WO2005017160A3 (en) Mobilization of hematopoietic cells

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05853080

Country of ref document: EP

Kind code of ref document: A2